CRIS Current Research Information System

FERRARI, ANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.889
AS - Asia 8.585
EU - Europa 6.391
AF - Africa 537
SA - Sud America 477
Continente sconosciuto - Info sul continente non disponibili 418
OC - Oceania 17
Totale 25.314
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.646
VN - Vietnam 2.547
SG - Singapore 2.167
CN - Cina 2.084
GB - Regno Unito 1.834
SE - Svezia 990
IT - Italia 799
DE - Germania 796
HK - Hong Kong 462
IN - India 444
FR - Francia 410
BR - Brasile 318
RU - Federazione Russa 314
IE - Irlanda 204
NL - Olanda 200
ZA - Sudafrica 161
CA - Canada 136
KR - Corea 133
JP - Giappone 127
EE - Estonia 124
CH - Svizzera 123
TG - Togo 120
UA - Ucraina 116
FI - Finlandia 111
BD - Bangladesh 107
NG - Nigeria 97
GR - Grecia 94
CI - Costa d'Avorio 74
BG - Bulgaria 71
AR - Argentina 66
PH - Filippine 66
IR - Iran 64
JO - Giordania 59
BE - Belgio 58
IQ - Iraq 43
TH - Thailandia 42
TR - Turchia 37
ID - Indonesia 34
PL - Polonia 34
SC - Seychelles 33
ES - Italia 30
AT - Austria 27
MX - Messico 27
CO - Colombia 21
UZ - Uzbekistan 21
PK - Pakistan 20
SA - Arabia Saudita 18
EC - Ecuador 17
MY - Malesia 17
TW - Taiwan 17
AU - Australia 14
PY - Paraguay 14
JM - Giamaica 13
PE - Perù 13
KZ - Kazakistan 12
HR - Croazia 11
VE - Venezuela 11
HN - Honduras 10
CL - Cile 9
CR - Costa Rica 9
TM - Turkmenistan 9
EG - Egitto 8
CZ - Repubblica Ceca 7
EU - Europa 7
GT - Guatemala 7
LB - Libano 7
TN - Tunisia 7
TT - Trinidad e Tobago 7
DZ - Algeria 6
IL - Israele 6
MU - Mauritius 6
NI - Nicaragua 6
QA - Qatar 6
AE - Emirati Arabi Uniti 5
BB - Barbados 5
PA - Panama 5
PT - Portogallo 5
RO - Romania 5
AL - Albania 4
AZ - Azerbaigian 4
ET - Etiopia 4
KE - Kenya 4
MA - Marocco 4
MK - Macedonia 4
OM - Oman 4
PR - Porto Rico 4
PS - Palestinian Territory 4
SK - Slovacchia (Repubblica Slovacca) 4
SV - El Salvador 4
UY - Uruguay 4
LA - Repubblica Popolare Democratica del Laos 3
NP - Nepal 3
NZ - Nuova Zelanda 3
RS - Serbia 3
SI - Slovenia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
BO - Bolivia 2
CU - Cuba 2
GE - Georgia 2
Totale 24.863
Salva come PNG Salva come JPEG
Città #
Southend 1.680
Singapore 1.530
Ashburn 857
Dong Ket 834
Chandler 715
Fairfield 602
San Jose 492
Hong Kong 444
Houston 398
Ann Arbor 365
Beijing 358
Ho Chi Minh City 340
Wilmington 340
Hanoi 307
Woodbridge 301
Santa Clara 285
Princeton 279
Seattle 278
Hefei 266
Boardman 216
Cambridge 209
Dublin 204
Council Bluffs 193
Nanjing 148
Westminster 147
Lauterbourg 142
Los Angeles 137
New York 134
Padova 134
Bologna 130
Lomé 120
Medford 115
Bern 110
Tokyo 106
Seoul 92
Helsinki 91
Abidjan 74
Berlin 72
Sofia 69
Frankfurt am Main 68
Jinan 68
Shenyang 67
Saint Petersburg 66
Hebei 64
Munich 63
Redmond 63
Chicago 62
Abeokuta 59
Milan 59
Amman 57
Brussels 57
Dallas 57
Buffalo 55
Da Nang 55
São Paulo 55
Redondo Beach 49
Bremen 47
Haiphong 47
Nanchang 46
Phoenix 45
Changsha 43
Guangzhou 43
Shanghai 40
Turin 39
Florence 38
Jiaxing 38
San Diego 38
Redwood City 37
Tianjin 37
Falls Church 35
Rome 34
Toronto 32
Norwalk 29
Hangzhou 26
Mountain View 26
Zhengzhou 26
Hyderabad 25
Bengaluru 24
Hải Dương 24
Montreal 24
Ningbo 24
Paris 24
Athens 23
Baghdad 22
Jacksonville 22
London 21
Orem 21
Bangkok 19
Taiyuan 19
Turku 19
Brooklyn 18
Haikou 18
Johannesburg 18
San Francisco 18
Tehran 18
Amsterdam 17
Istanbul 17
Warsaw 17
Atlanta 16
Biên Hòa 16
Totale 15.568
Salva come PNG Salva come JPEG
Nome #
A POLYMORPHISM IN THE CHROMOSOME 9P21 ANRIL LOCUS IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUSCEPTIBILITY 363
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 354
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 334
A HIGH SENSITIVE NANOFLUIDIC ARRAY IMPROVES THE DETECTION OF RARE COPIES OF BCR-ABL1 TRANSCRIPT IN PATIENTS WITH PHILADELPHIA POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 329
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 328
Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia 322
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia 314
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 309
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 297
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 285
Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients 282
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 275
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 272
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis 268
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 264
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 261
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 259
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis 256
CLINICAL OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/TLBL): THE BOLOGNA EXPERIENCE 256
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 254
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 249
Optimized pipeline of MuTect and GATK tools to improve the detection of somatic single nucleotide polymorphisms in whole-exome sequencing data 247
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 244
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 242
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 240
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 234
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF BY GENOMIC DELETIONS IS A FREQUENT EVENT IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS AND CONTRIBUTES TO DISEASE PROGRESSION 232
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 229
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 226
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 224
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF IS FREQUENTLY DELETED BUT NOT MUTATED IN BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS 224
The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients 222
Inhibition of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) is a novel therapeutic strategy in B- and T-Acute Lymphoblastic Leukemia (ALL). 221
Clustering Adult ACUTE Lymphoblastic Leukemia (ALL) Philadelphia Negative (Ph-) By Whole Exome Sequencing (WES) Analysis 221
Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia 219
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 217
RALE051: a novel established cell line of sporadic Burkitt lymphoma 213
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 212
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia 210
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 209
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. 208
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 208
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 204
BCR-ABL1 transcript detection in patients with Philadelphia-positive Acute Lymphoblastic Leukemia (ALL) using a new and high sensitive nanofluidic method 203
DEEP MOLECULAR CHARACTERIZATION OF ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BC-ALL) NEGATIVE FOR RECURRENT FUSION GENES REVEALS A HIGH COMPLEX GENETIC HETEROGENEITY INFLUENCING PROGNOSIS 202
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 201
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 199
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 197
Dissecting the Molecular Mechanisms of Aneuploidy in Acute Myeloid Leukemia By Next Generation Sequencing 195
Enhance the Efficacy of Doxorubicin Destabilizing the G2/M Checkpoint with a CHK1/CHK2 Inhibitor Pre-Treatment on Acute Lymphoblastic Leukemia 193
Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL) 192
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 192
EFFICACY AND FEASIBILITY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): A SINGLE-CENTER EXPERIENCE 189
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 188
The synergistic efficacy of Chk1/Chk2 inhibitors and doxorubicin in the treatment of acute lymphoblastic leukemia 188
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 187
FROM DIAGNOSIS TO RELAPSE: AN HIGH-RESOLUTION MOLECULAR ALLELOKARYOTYPING ANALYSIS OF PAIRED DIAGNOSIS-RELAPSE SAMPLES IN BCR-ABL1-POSITIVE ALL INDICATES INVOLVEMENT OF ALTERATIONS TARGETING KEY REGULATORS OF TUMOR SUPPRESSION, CELL CYCLE CONTROL, AND LYMPHOID/B CELL DEVELOPMENT 186
Clec12a: A new AML stem cell-associated antigen 184
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 183
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 183
TP53 Alterations Including Missense Mutations, Aberrant Exon-Junctions and Internal Intron Retentions Are Frequent and May Contribute to MDM2 Antagonist-Resistance in B-Acute Lymphoblastic leukemia 182
RNA Sequencing Reveals Novel and Rare Fusion Transcripts in Acute Myeloid Leukemia 179
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 179
IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients. 179
Override the doxorubicin-induced G2/M checkpoint using cell-cycle checkpoint inhibitors on acute lymphoblastic leukemia 177
CLINICAL OUTCOME OF T- ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA (T-ALL/T-LBL): THE BOLOGNA EXPERIENCE 175
SNP array reveals a new deletion of JAK2 in AML patients 175
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 173
GENETIC VARIATIONS IN ADH1A AND CYP2E1 STRONGLY AFFECTS RESPONSE AND TOXICITY TO A COMBINATION OF GEMTUZUMAB OZOGAMICIN PLUS FLUDARABINE, CYTARABINE, IDARUBICIN IN CD33-POSITIVE ACUTE MYELOID LEUKEMIA (AML) PATIENTS 172
THE RS564398, A POLYMORPHISM IN “THE ANTISENSE NON-CODING RNA IN THE INK4 LOCUS”, ANRIL, IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) SUSCEPTIBILITY 172
The Inhibition of Checkpoint Kinase 1 As a Promising Strategy to Increase the Effectiveness of Different Treatments in Acute Lymphoblastic Leukemia 170
Use of deep whole transcriptome sequencing in Philadelphia-positive acute lymphoblastic leukemia (ALL) to identify novel mutated genes and aberrant gene expression and alternative splicing profiles associated with disease progression. 169
NEXT GENERATION PAIRED END TRANSCRIPTOMIC RE-SEQUENCING TECHNOLOGY REVEALS NOVEL COMMON GENETIC ALTERATIONS IN THE HEDGEHOG PATHWAY IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 168
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 168
COMPLEX GENETIC HETEROGENEITY INFLUENCES PROGNOSIS IN ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA NEGATIVE FOR RECURRENT FUSION GENES 167
Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome 167
You have accessMine the Stability of the G2/M Checkpoint to Break Down Acute Lymphoblastic Leukemia Defenses Against Antineoplastic Drugs 166
Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome 166
LOSS OF CDKN2A GENE IS A POOR PROGNOSTIC MARKER IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS 164
MULTIPLEX PCR TO RAPIDLY IDENTIFY IKZF1 (IKAROS) GENE BREAKPOINTS IN BCRABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 164
Tp53 mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome 164
Genomic wide microarray analysis identifies novel copy number alterations in adult acute myeloid leukemia 163
The PAX5gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemiabut is not associated with outcome. A report on behalf of the GIMEMA AcuteLeukemia Working Party 162
Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response 162
Novel fusion transcripts identified by RNAseq cooperate with somatic mutations in the pathogenesis of acute myeloid leukemia 162
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse. 161
DEREGULATED EXPRESSION OF CHECKPOINT KINASE 1 (CHK1) IN BCR-ABL-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (BCR-ABL+ ALL) SUGGESTS A NEW THERAPEUTIC TARGET 159
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin 159
Expression of different isoforms of the B-cell mutator activation-induced cytidine deaminase (AID) in BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) Patients 158
SINGLE-AGENT INHIBITION OF CHECKPOINT KINASE 1 (CHK1) AND 2 (CHK2) BY PF-0477736 (PFIZER) AS A NEW PROMISING THERAPY IN B-ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 157
Next-Generation Sequencing Analysis Revealed That BCL11B Chromosomal Translocation Cooperates with Point Mutations in the Pathogenesis of Acute Myeloid Leukemia 157
PKC412 (Midostaurin) is safe and highly effective in Systemic Mastocytosis patients: follow up of a single-center Italian compassionate use 156
Genomic-Wide Analysis By High Resolution SNP Array Identifies Novel Genomic Alteration in Acute Myeloid Leukemia 156
SEVERAL FUSION TRANSCRIPTS ARE DETECTED BY NEXT GENERATION PAIRED END TRANSCRIPTOMIC RE-SEQUENCING APPROACH IN ADULT BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 153
IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients 150
IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis. 150
Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse 149
IKZF1 (IKAROS) DELETIONS IN BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA ARE ASSOCIATED WITH AN IMPAIRED B-CELL DIFFERENTIATION AND POOR OUTCOME 149
Recurrent gastrointestinal hemorrhage in treatment with dasatinib in a patient showing SMAD4 mutation with acute lymphoblastic leukemia Philadelphia positive and juvenile polyposis hereditary hemorrhagic telangiectasia syndrome 148
Whole Transcriptome Resequencing of Paired Diagnosis-Relapse BCR-ABL1-Positive Acute Lymphoblastic Leukemia (ALL) Samples Reveals the Loss of Cell Cycle Regulation as the Main Mechanism Responsible for Leukemia Progression 148
Totale 20.854
Salva come PNG Salva come JPEG
Categoria #
all - tutte 65.960
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.960
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.331 0 0 0 254 308 186 64 165 144 201 517 492
2022/20233.112 382 494 175 409 221 230 90 158 449 76 237 191
2023/2024799 30 114 26 78 53 184 49 61 49 32 56 67
2024/20252.888 136 491 253 198 363 114 241 87 26 260 122 597
2025/20267.078 557 571 529 434 772 368 702 318 1.687 657 251 232
2026/20271.139 187 273 629 50 0 0 0 0 0 0 0 0
Totale 25.314